Since the NF-κB pathway is associated with increased cytokine storm and exacerbated complications of COVID-19, inhibitors of the NF-κB pathway may be used in the clinical treatment of patients with COVID-19 (Hariharan et al., 2021). The gene discussed is NFKB1; the disease is COVID-19.